Seattle Genetics, Inc. (Nasdaq:SGEN) today announced four promotions and an appointment within the company’s commercial and operations teams. “These staff changes further enable the execution of our goals towards improving the lives of people with cancer,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “Chris and Chip have played key roles in the successful launch and ongoing commercialization of ADCETRIS in the United States and Canada. They both have strong backgrounds in oncology drug commercialization, combined with a science-based, patient-oriented approach. Kirk and Mark have been key leaders of the legal group for many years, successfully managing our legal, compliance and intellectual property functions. David brings more than 20 years of leadership experience in the biopharmaceutical industry, including a background in strategic portfolio and program management.” Chris Boerner, Ph.D., has been promoted to Executive Vice President, Commercial. Dr. Boerner has been with Seattle Genetics for more than three years, serving most recently as Senior Vice President, Commercial. He oversees all sales, marketing and market planning activities for ADCETRIS® (brentuximab vedotin). Prior to Seattle Genetics, he spent more than eight years at Genentech, a member of the Roche Group, where he served in a variety of commercial roles, including Director of Marketing on Avastin (bevacizumab) and Director of Avastin franchise management. Additionally, he served in a variety of commercial roles across multiple disease areas, including solid tumor oncology, lymphoma and immunology. Dr. Boerner joined Genentech from McKinsey & Company, a global strategic management consulting firm, where he worked on a variety of pharmaceutical sales and marketing engagements. Dr. Boerner received his Ph.D. and M.A. in Business Administration from the Haas School of Business at the University of California, Berkeley, and his A.B. in Economics and History from Washington University in St. Louis. Charles (Chip) R. Romp has been promoted to Senior Vice President, Sales. Mr. Romp joined Seattle Genetics in May 2010 to build the company’s field sales organization in advance of the U.S. Food and Drug Administration approval of ADCETRIS. Prior to his promotion to Senior Vice President, he served as Vice President, Sales. Mr. Romp was previously at Genentech, a member of the Roche Group, since 1998, most recently as National Sales Director for Avastin. During his tenure, he held several senior sales leadership positions for both oncology and immunology products, including Rituxan (rituximab) and Xolair (omalizumab), and was project lead for deployment recommendations for Genentech’s BioOncology sales forces. Mr. Romp received his B.A. from the University of Florida and his M.B.A. from Saint Leo University (formerly Saint Leo College) in Florida.